Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric ...

Rise of the armoured CARs (and the drive toward solid tumour) Cell therapy researchers love their ... presented new data on how it’s using CAR-macrophages to navigate the TME in patients with ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

View Full Profile. Learn about our Editorial Policies. Chimeric antigen receptor (CAR) T cell therapy leverages patients’ immune systems to fight cancer. This immunotherapy greatly expanded treatment ...

CAR-T cell therapy involves extracting a patient's T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body.

Chimeric antigen receptor (CAR) T-cell therapy is a promising field of cancer treatment that has shown great success in treating bloodborne cancers such as leukemia. It is a highly customized ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic ...

A study published in The Lancet Haematology has reported a 73% response rate for CAR T-cell therapy among patients with certain blood cancers. The clinical trials were conducted by researchers ...